Bridge Laboratories names Haijun (Lou) Dong as General Manager of Bridge Labs

Posted: April 27, 2009
BRIDGE LABORATORIES NAMES HAIJUN (LOU) DONG AS GENERAL MANAGER OF BRIDGE LABS (CHINA)

Gaithersburg MD USA -- Medical Industry E-Mail News Service™ -- April 16 2009 -- Bridge Laboratories has announced that Haijun (Lou) Dong, PhD and MBA, joined the company as the General Manager in Bridge’s Beijing, China, facility effective April 10, 2009.

Prior to joining Bridge, Dr. Dong served as member of the senior management team and head of DMPK and Drug Safety at Roche’s R Center in Shanghai for three years. While at Roche, Dr. Dong established and managed the operations, both internal and external, of physicochemical properties, DMPK, bioanalytical chemistry, and toxicology and safety pharmacology.

Dr. Dong worked at the University of Washington School of Pharmacy, Boehringer Ingelheim Pharmaceuticals in Ridgefield CT, and Roche Preclinical Research and Development in Nutley NJ, before returning to Shanghai, China.

In 2002, Dr. Dong was a Cofounder and General Manager of Shanghai Jahwa Pharmaceuticals, which was focused on the development and commercialization of generics and modified-release formulations. During his four-year tenure as the General Manager, the company successfully received 12 clinical trial and final marketing approvals from the SFDA (State Food and Drug Administration of China).

Dr. Dong received his PhD in Chemistry from the University of Washington in Seattle WA. Dr. Dong also holds a MBA from China Europe International Business School in Shanghai, China.

“Dr. Dong brings Bridge a wealth of experience in both pharmaceutical R and business management,” said Tom Oakley, President and CEO, Bridge Laboratories. “His experience in China and his understanding of building a start up will be instrumental to the success of our China lab,” Mr. Oakley continued.

About Bridge Laboratories:

Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory compliant drug development services globally. With over 17 years of experience and more than 1,800 in vivo toxicology studies completed; Bridge is dedicated to providing toxicology services to pharmaceutical and biotech companies in the US, Europe and Asia. Bridge is headquartered in Gaithersburg MD, and has laboratories in Maryland and China. Bridge’s AAALAC accredited facility in Beijing was among the first labs in China to perform GLP studies for clients worldwide. In 2008, the FDA and EMEA accepted data from Bridge’s facility in Beijing. For more information please visit website at: http://www.BridgeLaboratories.com.

Views: 46
Sponsors
Townie Perks
Townie® Poll
Do you do more or less endo procedures since you started practicing?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450